Unjustifiable Delays In Generic Competition? Biopharma Contends There Is No Problem

 
• By Brenda Sandburg

As Congress prepares to again debate patent reforms, brand industry says allegations of ‘patent thickets’ and extended market exclusivity are based on inaccurate or misleading data. They assert there is no need for PTO and FDA to institute systemic policy changes.

Drug competition
Patent system is not being misused to unjustifiably delay drug competition, biopharma reps tell USPTO and FDA • Source: Shutterstock

More from US FDA

More from Agency Leadership